Aurinia Pharmaceuticals (AUPH) Set to Announce Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect Aurinia Pharmaceuticals to post earnings of ($0.17) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03). The company had revenue of $45.10 million during the quarter, compared to the consensus estimate of $45.00 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative return on equity of 20.10%. The business’s revenue was up 58.8% compared to the same quarter last year. During the same period last year, the company earned ($0.18) earnings per share. On average, analysts expect Aurinia Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $5.03 on Thursday. The company has a debt-to-equity ratio of 0.20, a current ratio of 5.50 and a quick ratio of 4.99. The stock has a 50-day moving average of $5.31 and a 200-day moving average of $7.22. Aurinia Pharmaceuticals has a one year low of $4.71 and a one year high of $12.43. The stock has a market cap of $727.43 million, a PE ratio of -9.31 and a beta of 1.36.

Analyst Ratings Changes

AUPH has been the subject of several recent analyst reports. Jefferies Financial Group cut their price objective on Aurinia Pharmaceuticals from $9.50 to $9.00 and set a “hold” rating for the company in a report on Friday, February 16th. Royal Bank of Canada cut their price objective on Aurinia Pharmaceuticals from $13.00 to $8.00 and set an “outperform” rating for the company in a report on Friday, February 16th. Cantor Fitzgerald dropped their price target on Aurinia Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Friday, February 23rd. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Aurinia Pharmaceuticals in a research note on Friday, March 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.